1dn2 › Citations

Convergent solutions to binding at a protein-protein interface.

DeLano WL, Ultsch MH, de Vos AM, Wells JA
Science 287 1279-83 (2000)
Cited: 385 times
EuropePMC logo PMID: 10678837

Abstract

The hinge region on the Fc fragment of human immunoglobulin G interacts with at least four different natural protein scaffolds that bind at a common site between the C(H2) and C(H3) domains. This "consensus" site was also dominant for binding of random peptides selected in vitro for high affinity (dissociation constant, about 25 nanomolar) by bacteriophage display. Thus, this site appears to be preferred owing to its intrinsic physiochemical properties, and not for biological function alone. A 2.7 angstrom crystal structure of a selected 13-amino acid peptide in complex with Fc demonstrated that the peptide adopts a compact structure radically different from that of the other Fc binding proteins. Nevertheless, the specific Fc binding interactions of the peptide strongly mimic those of the other proteins. Juxtaposition of the available Fc-complex crystal structures showed that the convergent binding surface is highly accessible, adaptive, and hydrophobic and contains relatively few sites for polar interactions. These are all properties that may promote cross-reactive binding, which is common to protein-protein interactions and especially hormone-receptor complexes.

Reviews - 1dn2 mentioned but not cited (5)

  1. Neonatal Fc receptor and IgG-based therapeutics. Kuo TT, Aveson VG. MAbs 3 422-430 (2011)
  2. Function and 3D structure of the N-glycans on glycoproteins. Nagae M, Yamaguchi Y. Int J Mol Sci 13 8398-8429 (2012)
  3. Fc-Binding Ligands of Immunoglobulin G: An Overview of High Affinity Proteins and Peptides. Choe W, Durgannavar TA, Chung SJ. Materials (Basel) 9 E994 (2016)
  4. Max Bergmann lecture protein epitope mimetics in the age of structural vaccinology. Robinson JA. J Pept Sci 19 127-140 (2013)
  5. Affinity-Based Methods for Site-Specific Conjugation of Antibodies. von Witting E, Hober S, Kanje S. Bioconjug Chem 32 1515-1524 (2021)

Articles - 1dn2 mentioned but not cited (25)

  1. Applying physics-based scoring to calculate free energies of binding for single amino acid mutations in protein-protein complexes. Beard H, Cholleti A, Pearlman D, Sherman W, Loving KA. PLoS One 8 e82849 (2013)
  2. NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic. Barb AW, Prestegard JH. Nat Chem Biol 7 147-153 (2011)
  3. Structural characterization of anti-inflammatory immunoglobulin G Fc proteins. Ahmed AA, Giddens J, Pincetic A, Lomino JV, Ravetch JV, Wang LX, Bjorkman PJ. J Mol Biol 426 3166-3179 (2014)
  4. Identification of hot-spot residues in protein-protein interactions by computational docking. Grosdidier S, Fernández-Recio J. BMC Bioinformatics 9 447 (2008)
  5. Crystal structure of the HSV-1 Fc receptor bound to Fc reveals a mechanism for antibody bipolar bridging. Sprague ER, Wang C, Baker D, Bjorkman PJ. PLoS Biol 4 e148 (2006)
  6. Towards inferring time dimensionality in protein-protein interaction networks by integrating structures: the p53 example. Tuncbag N, Kar G, Gursoy A, Keskin O, Nussinov R. Mol Biosyst 5 1770-1778 (2009)
  7. Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica. Soltys J, Liu Y, Ritchie A, Wemlinger S, Schaller K, Schumann H, Owens GP, Bennett JL. J Clin Invest 129 2000-2013 (2019)
  8. Computational design of a pH-sensitive IgG binding protein. Strauch EM, Fleishman SJ, Baker D. Proc Natl Acad Sci U S A 111 675-680 (2014)
  9. Computationally Designed Bispecific Antibodies using Negative State Repertoires. Leaver-Fay A, Froning KJ, Atwell S, Aldaz H, Pustilnik A, Lu F, Huang F, Yuan R, Hassanali S, Chamberlain AK, Fitchett JR, Demarest SJ, Kuhlman B. Structure 24 641-651 (2016)
  10. Crystal structure of a human autoimmune complex between IgM rheumatoid factor RF61 and IgG1 Fc reveals a novel epitope and evidence for affinity maturation. Duquerroy S, Stura EA, Bressanelli S, Fabiane SM, Vaney MC, Beale D, Hamon M, Casali P, Rey FA, Sutton BJ, Taussig MJ. J Mol Biol 368 1321-1331 (2007)
  11. A synthetic mimic of human Fc receptors: defined chemical modification of cell surfaces enables efficient endocytic uptake of human immunoglobulin-G. Boonyarattanakalin S, Martin SE, Sun Q, Peterson BR. J Am Chem Soc 128 11463-11470 (2006)
  12. Conformational flexibility in immunoglobulin E-Fc 3-4 revealed in multiple crystal forms. Wurzburg BA, Jardetzky TS. J Mol Biol 393 176-190 (2009)
  13. Fusion of a short peptide that binds immunoglobulin G to a recombinant protein substantially increases its plasma half-life in mice. Sockolosky JT, Kivimäe S, Szoka FC. PLoS One 9 e102566 (2014)
  14. X-ray crystal structures of monomeric and dimeric peptide inhibitors in complex with the human neonatal Fc receptor, FcRn. Mezo AR, Sridhar V, Badger J, Sakorafas P, Nienaber V. J Biol Chem 285 27694-27701 (2010)
  15. 3-2-1: Structural insights from stepwise shrinkage of a three-helix Fc-binding domain to a single helix. Ultsch M, Braisted A, Maun HR, Eigenbrot C. Protein Eng Des Sel 30 619-625 (2017)
  16. IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies. Bi W, Xu W, Cheng L, Xue J, Wang Q, Yu F, Xia S, Wang Q, Li G, Qin C, Lu L, Su L, Jiang S. PLoS Pathog 15 e1008082 (2019)
  17. Template directed synthesis of antibody Fc conjugates with concomitant ligand release. Postupalenko V, Marx L, Viertl D, Gsponer N, Gasilova N, Denoel T, Schaefer N, Prior JO, Hagens G, Lévy F, Garrouste P, Segura JM, Nyanguile O. Chem Sci 13 3965-3976 (2022)
  18. A rational approach to enhancing antibody Fc homodimer formation for robust production of antibody mixture in a single cell line. Yu J, Wang X, Xu T, Jin Q, Duan J, Wu J, Wu H, Xu T, Ye S. J Biol Chem 292 17885-17896 (2017)
  19. Kinetics-Based Structural Requirements of Human Immunoglobulin G Binding Peptides. Muguruma K, Fujita K, Fukuda A, Kishimoto S, Sakamoto S, Arima R, Ito M, Kawasaki M, Nakano S, Ito S, Shimizu K, Taguchi A, Takayama K, Taniguchi A, Ito Y, Hayashi Y. ACS Omega 4 14390-14397 (2019)
  20. Prediction of hot spots in protein interfaces using extreme learning machines with the information of spatial neighbour residues. Wang L, Zhang W, Gao Q, Xiong C. IET Syst Biol 8 184-190 (2014)
  21. Development of a dual-functional conjugate of antigenic peptide and Fc-III mimetics (DCAF) for targeted antibody blocking. Zhang L, Shen H, Gong Y, Pang X, Yi M, Guo L, Li J, Arroyo S, Lu X, Ovchinnikov S, Cheng G, Liu X, Jiang X, Feng S, Deng H, Deng H. Chem Sci 10 3271-3280 (2019)
  22. Antibody mix-and-read assays based on fluorescence intensity probes. Patil U, Goyal A, Vu B, Liu Y, Maranholkar V, Kourentzi K, Briggs JM, Willson RC. MAbs 13 1980178 (2021)
  23. Site-selective template-directed synthesis of antibody Fc conjugates with concomitant ligand release. Postupalenko V, Marx L, Pantin M, Viertl D, Gsponer N, Giudice G, Gasilova N, Schottelius M, Lévy F, Garrouste P, Segura JM, Nyanguile O. Chem Sci 15 1324-1337 (2024)
  24. IgG Fc-Binding Peptide-Conjugated Pan-CoV Fusion Inhibitor Exhibits Extended In Vivo Half-Life and Synergistic Antiviral Effect When Combined with Neutralizing Antibodies. Su X, Huang Z, Xu W, Wang Q, Xing L, Lu L, Jiang S, Xia S. Biomolecules 13 1283 (2023)
  25. Synthesis and structure-activity relationship studies of IgG-binding peptides focused on the C-terminal histidine residue. Muguruma K, Ito M, Fukuda A, Kishimoto S, Taguchi A, Takayama K, Taniguchi A, Ito Y, Hayashi Y. Medchemcomm 10 1789-1795 (2019)


Reviews citing this publication (84)

  1. Fcgamma receptors as regulators of immune responses. Nimmerjahn F, Ravetch JV. Nat Rev Immunol 8 34-47 (2008)
  2. FcRn: the neonatal Fc receptor comes of age. Roopenian DC, Akilesh S. Nat Rev Immunol 7 715-725 (2007)
  3. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Wells JA, McClendon CL. Nature 450 1001-1009 (2007)
  4. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Arkin MR, Wells JA. Nat Rev Drug Discov 3 301-317 (2004)
  5. Principles of docking: An overview of search algorithms and a guide to scoring functions. Halperin I, Ma B, Wolfson H, Nussinov R. Proteins 47 409-443 (2002)
  6. Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. Arkin MR, Tang Y, Wells JA. Chem Biol 21 1102-1114 (2014)
  7. Is allostery an intrinsic property of all dynamic proteins? Gunasekaran K, Ma B, Nussinov R. Proteins 57 433-443 (2004)
  8. Hot spots--a review of the protein-protein interface determinant amino-acid residues. Moreira IS, Fernandes PA, Ramos MJ. Proteins 68 803-812 (2007)
  9. Structure-Based Design of Inhibitors of Protein-Protein Interactions: Mimicking Peptide Binding Epitopes. Pelay-Gimeno M, Glas A, Koch O, Grossmann TN. Angew Chem Int Ed Engl 54 8896-8927 (2015)
  10. Multiple diverse ligands binding at a single protein site: a matter of pre-existing populations. Ma B, Shatsky M, Wolfson HJ, Nussinov R. Protein Sci 11 184-197 (2002)
  11. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Hogarth PM, Pietersz GA. Nat Rev Drug Discov 11 311-331 (2012)
  12. Human antibody-Fc receptor interactions illuminated by crystal structures. Woof JM, Burton DR. Nat Rev Immunol 4 89-99 (2004)
  13. The molecular basis of TCR germline bias for MHC is surprisingly simple. Garcia KC, Adams JJ, Feng D, Ely LK. Nat Immunol 10 143-147 (2009)
  14. Oncogenic protein interfaces: small molecules, big challenges. Nero TL, Morton CJ, Holien JK, Wielens J, Parker MW. Nat Rev Cancer 14 248-262 (2014)
  15. Phage display in pharmaceutical biotechnology. Sidhu SS. Curr Opin Biotechnol 11 610-616 (2000)
  16. Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity. Smith MC, Gestwicki JE. Expert Rev Mol Med 14 e16 (2012)
  17. Antagonists of protein-protein interactions. Cochran AG. Chem Biol 7 R85-94 (2000)
  18. Cell-division inhibitors: new insights for future antibiotics. Lock RL, Harry EJ. Nat Rev Drug Discov 7 324-338 (2008)
  19. The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. Sockolosky JT, Szoka FC. Adv Drug Deliv Rev 91 109-124 (2015)
  20. Phage display: selecting straws instead of a needle from a haystack. Vodnik M, Zager U, Strukelj B, Lunder M. Molecules 16 790-817 (2011)
  21. Human IgG4: a structural perspective. Davies AM, Sutton BJ. Immunol Rev 268 139-159 (2015)
  22. Exploring protein-protein interactions with phage display. Sidhu SS, Fairbrother WJ, Deshayes K. Chembiochem 4 14-25 (2003)
  23. The nature of target-unrelated peptides recovered in the screening of phage-displayed random peptide libraries with antibodies. Menendez A, Scott JK. Anal Biochem 336 145-157 (2005)
  24. Rheumatoid factors: host resistance or autoimmunity? Newkirk MM. Clin Immunol 104 1-13 (2002)
  25. Recognition of immunoglobulins by Fcgamma receptors. Radaev S, Sun P. Mol Immunol 38 1073-1083 (2002)
  26. Hsp70 protein complexes as drug targets. Assimon VA, Gillies AT, Rauch JN, Gestwicki JE. Curr Pharm Des 19 404-417 (2013)
  27. Membrane-bound diiron carboxylate proteins. Berthold DA, Stenmark P. Annu Rev Plant Biol 54 497-517 (2003)
  28. Protein functional epitopes: hot spots, dynamics and combinatorial libraries. Ma B, Wolfson HJ, Nussinov R. Curr Opin Struct Biol 11 364-369 (2001)
  29. State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors. Sheng C, Dong G, Miao Z, Zhang W, Wang W. Chem Soc Rev 44 8238-8259 (2015)
  30. The design, structures and therapeutic potential of protein epitope mimetics. Robinson JA, Demarco S, Gombert F, Moehle K, Obrecht D. Drug Discov Today 13 944-951 (2008)
  31. Macrocycles as protein-protein interaction inhibitors. Dougherty PG, Qian Z, Pei D. Biochem J 474 1109-1125 (2017)
  32. Disruption of protein-protein interactions: towards new targets for chemotherapy. Loregian A, Palù G. J Cell Physiol 204 750-762 (2005)
  33. Mechanistic diversity of cytokine receptor signaling across cell membranes. Stroud RM, Wells JA. Sci STKE 2004 re7 (2004)
  34. Computational prediction of protein hot spot residues. Morrow JK, Zhang S. Curr Pharm Des 18 1255-1265 (2012)
  35. LG/LNS domains: multiple functions -- one business end? Rudenko G, Hohenester E, Muller YA. Trends Biochem Sci 26 363-368 (2001)
  36. The many faces of Ras: recognition of small GTP-binding proteins. Corbett KD, Alber T. Trends Biochem Sci 26 710-716 (2001)
  37. Complexity and simplicity of ligand-macromolecule interactions: the energy landscape perspective. Verkhivker GM, Bouzida D, Gehlhaar DK, Rejto PA, Freer ST, Rose PW. Curr Opin Struct Biol 12 197-203 (2002)
  38. Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics. Zorzi A, Linciano S, Angelini A. Medchemcomm 10 1068-1081 (2019)
  39. TRIM21 and the Function of Antibodies inside Cells. Rhodes DA, Isenberg DA. Trends Immunol 38 916-926 (2017)
  40. News from the protein mutability landscape. Hecht M, Bromberg Y, Rost B. J Mol Biol 425 3937-3948 (2013)
  41. Exploring privileged structures: the combinatorial synthesis of cyclic peptides. Horton DA, Bourne GT, Smythe ML. Mol Divers 5 289-304 (2002)
  42. Luxury accommodations: the expanding role of structural plasticity in protein-protein interactions. Sundberg EJ, Mariuzza RA. Structure 8 R137-42 (2000)
  43. Antibody Aggregation: Insights from Sequence and Structure. Li W, Prabakaran P, Chen W, Zhu Z, Feng Y, Dimitrov DS. Antibodies (Basel) 5 E19 (2016)
  44. Exploring privileged structures: the combinatorial synthesis of cyclic peptides. Horton DA, Bourne GT, Smythe ML. J Comput Aided Mol Des 16 415-430 (2002)
  45. Piecing together the family portrait of TCR-CD3 complexes. Kuhns MS, Badgandi HB. Immunol Rev 250 120-143 (2012)
  46. Lessons from Hot Spot Analysis for Fragment-Based Drug Discovery. Hall DR, Kozakov D, Whitty A, Vajda S. Trends Pharmacol Sci 36 724-736 (2015)
  47. Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery. Hallenbeck KK, Turner DM, Renslo AR, Arkin MR. Curr Top Med Chem 17 4-15 (2017)
  48. The paramyxovirus polymerase complex as a target for next-generation anti-paramyxovirus therapeutics. Cox R, Plemper RK. Front Microbiol 6 459 (2015)
  49. Multiple paths to multispecificity. Mariuzza RA. Immunity 24 359-361 (2006)
  50. G protein betagamma subunits as targets for small molecule therapeutic development. Smrcka AV, Lehmann DM, Dessal AL. Comb Chem High Throughput Screen 11 382-395 (2008)
  51. Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies. Le NP, Bowden TA, Struwe WB, Crispin M. Biochim Biophys Acta 1860 1655-1668 (2016)
  52. Peptide interactions with G-protein coupled receptors. Marshall GR. Biopolymers 60 246-277 (2001)
  53. Synthetic cell surface receptors for delivery of therapeutics and probes. Hymel D, Peterson BR. Adv Drug Deliv Rev 64 797-810 (2012)
  54. New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics. Smith AJ. J Biomol Screen 20 437-453 (2015)
  55. Affinity chromatography: A versatile technique for antibody purification. Arora S, Saxena V, Ayyar BV. Methods 116 84-94 (2017)
  56. One from column A and two from column B: the benefits of phage display in molecular-recognition studies. Rodi DJ, Makowski L, Kay BK. Curr Opin Chem Biol 6 92-96 (2002)
  57. In silico Approaches for the Design and Optimization of Interfering Peptides Against Protein-Protein Interactions. Hashemi ZS, Zarei M, Fath MK, Ganji M, Farahani MS, Afsharnouri F, Pourzardosht N, Khalesi B, Jahangiri A, Rahbar MR, Khalili S. Front Mol Biosci 8 669431 (2021)
  58. Multiple ligand binding sites on domain seven of human complement factor H. Giannakis E, Male DA, Ormsby RJ, Mold C, Jokiranta TS, Ranganathan S, Gordon DL. Int Immunopharmacol 1 433-443 (2001)
  59. Survey of the year 2000 commercial optical biosensor literature. Rich RL, Myszka DG. J Mol Recognit 14 273-294 (2001)
  60. Protein interaction networks as starting points to identify novel antimicrobial drug targets. Zoraghi R, Reiner NE. Curr Opin Microbiol 16 566-572 (2013)
  61. Interactions between immunoglobulin G molecules. Nezlin R. Immunol Lett 132 1-5 (2010)
  62. Structural insights into the interactions between human IgE and its high affinity receptor FcepsilonRI. Wurzburg BA, Jardetzky TS. Mol Immunol 38 1063-1072 (2002)
  63. G-protein-directed ligand discovery with peptide combinatorial libraries. Ja WW, Roberts RW. Trends Biochem Sci 30 318-324 (2005)
  64. Precision Modification of Native Antibodies. Wu KL, Yu C, Lee C, Zuo C, Ball ZT, Xiao H. Bioconjug Chem 32 1947-1959 (2021)
  65. Protein therapeutics: promises and challenges for the 21st century. Weng Z, DeLisi C. Trends Biotechnol 20 29-35 (2002)
  66. Engineered protein scaffolds as leads for synthetic inhibitors of protein-protein interactions. Wuo MG, Arora PS. Curr Opin Chem Biol 44 16-22 (2018)
  67. Techniques for molecular imaging probe design. Reynolds F, Kelly KA. Mol Imaging 10 407-419 (2011)
  68. New perspectives on the design of cytokines and growth factors. Kallen KJ, Grötzinger J, Rose-John S. Trends Biotechnol 18 455-461 (2000)
  69. Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy. Finke JM, Banks WA. Hum Antibodies 25 131-146 (2017)
  70. Small and Simple, yet Sturdy: Conformationally Constrained Peptides with Remarkable Properties. Bozovičar K, Bratkovič T. Int J Mol Sci 22 1611 (2021)
  71. Structurally adaptive hot spots at a protein interaction interface on TRAF3. Ely KR, Li C. J Mol Recognit 15 286-290 (2002)
  72. Antibody recruiting molecules (ARMs): synthetic immunotherapeutics to fight cancer. Achilli S, Berthet N, Renaudet O. RSC Chem Biol 2 713-724 (2021)
  73. Nonimmune antibody interactions of Group A Streptococcus M and M-like proteins. Mills JO, Ghosh P. PLoS Pathog 17 e1009248 (2021)
  74. Moonlighting enzymes: when cellular context defines specificity. Gupta MN, Uversky VN. Cell Mol Life Sci 80 130 (2023)
  75. Protein-Protein Interactions in Translesion Synthesis. Dash RC, Hadden K. Molecules 26 5544 (2021)
  76. Circulating non-immune IgG complexes in health and disease. Nezlin R. Immunol Lett 122 141-144 (2009)
  77. PDZ domains and their ligands. Kay BK, Kehoe JW. Chem Biol 11 423-425 (2004)
  78. [Therapeutic agents targetting protein-protein interactions: myth or reality?]. Laudet B, Prudent R, Filhol O, Cochet C. Med Sci (Paris) 23 273-278 (2007)
  79. IgG Fc Affinity Ligands and Their Applications in Antibody-Involved Drug Delivery: A Brief Review. Yang C, He B, Zhang H, Wang X, Zhang Q, Dai W. Pharmaceutics 15 187 (2023)
  80. Peptide Affinity Chromatography Applied to Therapeutic Antibodies Purification. Barredo-Vacchelli GR, Giudicessi SL, Martínez-Ceron MC, Cascone O, Camperi SA. Int J Pept Res Ther 27 2905-2921 (2021)
  81. Peptidomimetics in cancer chemotherapy. Avendaño C, Menéndez JC. Clin Transl Oncol 9 563-570 (2007)
  82. Overcoming phenotypic switching: targeting protein-protein interactions in cancer. Ladias C, Papakotoulas P, Papaioannou M, Papanikolaou NA. Explor Target Antitumor Ther 4 1071-1081 (2023)
  83. Recent Developments and Future Perspectives of Purine Derivatives as a Promising Scaffold in Drug Discovery. Rana N, Grover P, Singh H. Curr Top Med Chem 24 541-579 (2024)
  84. Structural Basis of a Conventional Recognition Mode of IGHV1-69 Rheumatoid Factors. Shiroishi M. Adv Exp Med Biol 21 171-182 (2021)

Articles citing this publication (271)

  1. Complement is activated by IgG hexamers assembled at the cell surface. Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, Voorhorst M, Ugurlar D, Rosati S, Heck AJ, van de Winkel JG, Wilson IA, Koster AJ, Taylor RP, Saphire EO, Burton DR, Schuurman J, Gros P, Parren PW. Science 343 1260-1263 (2014)
  2. Protein-protein interactions: structurally conserved residues distinguish between binding sites and exposed protein surfaces. Ma B, Elkayam T, Wolfson H, Nussinov R. Proc Natl Acad Sci U S A 100 5772-5777 (2003)
  3. Design of therapeutic proteins with enhanced stability. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Proc Natl Acad Sci U S A 106 11937-11942 (2009)
  4. The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins. Kozakov D, Grove LE, Hall DR, Bohnuud T, Mottarella SE, Luo L, Xia B, Beglov D, Vajda S. Nat Protoc 10 733-755 (2015)
  5. Hot regions in protein--protein interactions: the organization and contribution of structurally conserved hot spot residues. Keskin O, Ma B, Nussinov R. J Mol Biol 345 1281-1294 (2005)
  6. ProMate: a structure based prediction program to identify the location of protein-protein binding sites. Neuvirth H, Raz R, Schreiber G. J Mol Biol 338 181-199 (2004)
  7. Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function. James LC, Keeble AH, Khan Z, Rhodes DA, Trowsdale J. Proc Natl Acad Sci U S A 104 6200-6205 (2007)
  8. Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Martin WL, West AP, Gan L, Bjorkman PJ. Mol Cell 7 867-877 (2001)
  9. The use of mRNA display to select high-affinity protein-binding peptides. Wilson DS, Keefe AD, Szostak JW. Proc Natl Acad Sci U S A 98 3750-3755 (2001)
  10. Binding of small molecules to an adaptive protein-protein interface. Arkin MR, Randal M, DeLano WL, Hyde J, Luong TN, Oslob JD, Raphael DR, Taylor L, Wang J, McDowell RS, Wells JA, Braisted AC. Proc Natl Acad Sci U S A 100 1603-1608 (2003)
  11. Insights into antiparallel microtubule crosslinking by PRC1, a conserved nonmotor microtubule binding protein. Subramanian R, Wilson-Kubalek EM, Arthur CP, Bick MJ, Campbell EA, Darst SA, Milligan RA, Kapoor TM. Cell 142 433-443 (2010)
  12. Insights into IgA-mediated immune responses from the crystal structures of human FcalphaRI and its complex with IgA1-Fc. Herr AB, Ballister ER, Bjorkman PJ. Nature 423 614-620 (2003)
  13. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. Matsumiya S, Yamaguchi Y, Saito J, Nagano M, Sasakawa H, Otaki S, Satoh M, Shitara K, Kato K. J Mol Biol 368 767-779 (2007)
  14. Conservation and relative importance of residues across protein-protein interfaces. Guharoy M, Chakrabarti P. Proc Natl Acad Sci U S A 102 15447-15452 (2005)
  15. Contrasting IgG structures reveal extreme asymmetry and flexibility. Saphire EO, Stanfield RL, Crispin MD, Parren PW, Rudd PM, Dwek RA, Burton DR, Wilson IA. J Mol Biol 319 9-18 (2002)
  16. Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display. Steiner D, Forrer P, Plückthun A. J Mol Biol 382 1211-1227 (2008)
  17. Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes. Huai Q, Kim HY, Liu Y, Zhao Y, Mondragon A, Liu JO, Ke H. Proc Natl Acad Sci U S A 99 12037-12042 (2002)
  18. A new, structurally nonredundant, diverse data set of protein-protein interfaces and its implications. Keskin O, Tsai CJ, Wolfson H, Nussinov R. Protein Sci 13 1043-1055 (2004)
  19. TRIM21 is an IgG receptor that is structurally, thermodynamically, and kinetically conserved. Keeble AH, Khan Z, Forster A, James LC. Proc Natl Acad Sci U S A 105 6045-6050 (2008)
  20. A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface. de Jong RN, Beurskens FJ, Verploegen S, Strumane K, van Kampen MD, Voorhorst M, Horstman W, Engelberts PJ, Oostindie SC, Wang G, Heck AJ, Schuurman J, Parren PW. PLoS Biol 14 e1002344 (2016)
  21. The Structural Role of Antibody N-Glycosylation in Receptor Interactions. Subedi GP, Barb AW. Structure 23 1573-1583 (2015)
  22. Mitochondrial Protein Synthesis Adapts to Influx of Nuclear-Encoded Protein. Richter-Dennerlein R, Oeljeklaus S, Lorenzi I, Ronsör C, Bareth B, Schendzielorz AB, Wang C, Warscheid B, Rehling P, Dennerlein S. Cell 167 471-483.e10 (2016)
  23. Automated and fast building of three-dimensional RNA structures. Zhao Y, Huang Y, Gong Z, Wang Y, Man J, Xiao Y. Sci Rep 2 734 (2012)
  24. Similar binding sites and different partners: implications to shared proteins in cellular pathways. Keskin O, Nussinov R. Structure 15 341-354 (2007)
  25. Two different T cell receptors use different thermodynamic strategies to recognize the same peptide/MHC ligand. Davis-Harrison RL, Armstrong KM, Baker BM. J Mol Biol 346 533-550 (2005)
  26. A feature-based approach to modeling protein-protein interaction hot spots. Cho KI, Kim D, Lee D. Nucleic Acids Res 37 2672-2687 (2009)
  27. A molecular basis for integrin alphaMbeta 2 ligand binding promiscuity. Yakubenko VP, Lishko VK, Lam SC, Ugarova TP. J Biol Chem 277 48635-48642 (2002)
  28. Convergent mechanisms for recognition of divergent cytokines by the shared signaling receptor gp130. Boulanger MJ, Bankovich AJ, Kortemme T, Baker D, Garcia KC. Mol Cell 12 577-589 (2003)
  29. Recognition of eIF4G by rotavirus NSP3 reveals a basis for mRNA circularization. Groft CM, Burley SK. Mol Cell 9 1273-1283 (2002)
  30. Identification of protein oligomerization states by analysis of interface conservation. Elcock AH, McCammon JA. Proc Natl Acad Sci U S A 98 2990-2994 (2001)
  31. Protein-protein interactions; coupling of structurally conserved residues and of hot spots across interfaces. Implications for docking. Halperin I, Wolfson H, Nussinov R. Structure 12 1027-1038 (2004)
  32. Aggregation-prone motifs in human immunoglobulin G. Chennamsetty N, Helk B, Voynov V, Kayser V, Trout BL. J Mol Biol 391 404-413 (2009)
  33. Structural determinants of unique properties of human IgG4-Fc. Davies AM, Rispens T, Ooijevaar-de Heer P, Gould HJ, Jefferis R, Aalberse RC, Sutton BJ. J Mol Biol 426 630-644 (2014)
  34. The specificity of cross-reactivity: promiscuous antibody binding involves specific hydrogen bonds rather than nonspecific hydrophobic stickiness. James LC, Tawfik DS. Protein Sci 12 2183-2193 (2003)
  35. Receptor for Fc on the surfaces of schistosomes. Loukas A, Jones MK, King LT, Brindley PJ, McManus DP. Infect Immun 69 3646-3651 (2001)
  36. Symmetry recognizing asymmetry: analysis of the interactions between the C-type lectin-like immunoreceptor NKG2D and MHC class I-like ligands. McFarland BJ, Kortemme T, Yu SF, Baker D, Strong RK. Structure 11 411-422 (2003)
  37. Asymmetric Molecular Architecture of the Human γ-Tubulin Ring Complex. Wieczorek M, Urnavicius L, Ti SC, Molloy KR, Chait BT, Kapoor TM. Cell 180 165-175.e16 (2020)
  38. Design of multi-specificity in protein interfaces. Humphris EL, Kortemme T. PLoS Comput Biol 3 e164 (2007)
  39. Prospective identification of parasitic sequences in phage display screens. Matochko WL, Cory Li S, Tang SK, Derda R. Nucleic Acids Res 42 1784-1798 (2014)
  40. The nuclear pore complex-associated protein, Mlp2p, binds to the yeast spindle pole body and promotes its efficient assembly. Niepel M, Strambio-de-Castillia C, Fasolo J, Chait BT, Rout MP. J Cell Biol 170 225-235 (2005)
  41. Hot spot-based design of small-molecule inhibitors for protein-protein interactions. Guo W, Wisniewski JA, Ji H. Bioorg Med Chem Lett 24 2546-2554 (2014)
  42. Change in protein flexibility upon complex formation: analysis of Ras-Raf using molecular dynamics and a molecular framework approach. Gohlke H, Kuhn LA, Case DA. Proteins 56 322-337 (2004)
  43. Thermodynamic analysis of degenerate recognition by the NKG2D immunoreceptor: not induced fit but rigid adaptation. McFarland BJ, Strong RK. Immunity 19 803-812 (2003)
  44. Solution structure of DFF40 and DFF45 N-terminal domain complex and mutual chaperone activity of DFF40 and DFF45. Zhou P, Lugovskoy AA, McCarty JS, Li P, Wagner G. Proc Natl Acad Sci U S A 98 6051-6055 (2001)
  45. Structure of the human IgE-Fc C epsilon 3-C epsilon 4 reveals conformational flexibility in the antibody effector domains. Wurzburg BA, Garman SC, Jardetzky TS. Immunity 13 375-385 (2000)
  46. Recombinant human factor VIII-specific affinity ligands selected from phage-displayed combinatorial libraries of protein A. Nord K, Nord O, Uhlén M, Kelley B, Ljungqvist C, Nygren PA. Eur J Biochem 268 4269-4277 (2001)
  47. TRIM21 is a trimeric protein that binds IgG Fc via the B30.2 domain. Rhodes DA, Trowsdale J. Mol Immunol 44 2406-2414 (2007)
  48. A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. Dong J, Thompson AA, Fan Y, Lou J, Conrad F, Ho M, Pires-Alves M, Wilson BA, Stevens RC, Marks JD. J Mol Biol 397 1106-1118 (2010)
  49. Structure-based method for analyzing protein-protein interfaces. Gao Y, Wang R, Lai L. J Mol Model 10 44-54 (2004)
  50. Molecular discrimination inside polymer nanotubules. Savariar EN, Krishnamoorthy K, Thayumanavan S. Nat Nanotechnol 3 112-117 (2008)
  51. Nonnatural protein-protein interaction-pair design by key residues grafting. Liu S, Liu S, Zhu X, Liang H, Cao A, Chang Z, Lai L. Proc Natl Acad Sci U S A 104 5330-5335 (2007)
  52. Structural basis for recognition by an in vitro evolved affibody. Högbom M, Eklund M, Nygren PA, Nordlund P. Proc Natl Acad Sci U S A 100 3191-3196 (2003)
  53. Evidence for a functional sidedness to the alphabetaTCR. Kuhns MS, Girvin AT, Klein LO, Chen R, Jensen KD, Newell EW, Huppa JB, Lillemeier BF, Huse M, Chien YH, Garcia KC, Davis MM. Proc Natl Acad Sci U S A 107 5094-5099 (2010)
  54. Structure-based discovery of an inhibitor of Arf activation by Sec7 domains through targeting of protein-protein complexes. Viaud J, Zeghouf M, Barelli H, Zeeh JC, Padilla A, Guibert B, Chardin P, Royer CA, Cherfils J, Chavanieu A. Proc Natl Acad Sci U S A 104 10370-10375 (2007)
  55. Side-chain conformational entropy at protein-protein interfaces. Cole C, Warwicker J. Protein Sci 11 2860-2870 (2002)
  56. Functional analysis of the Bacillus subtilis morphogenetic spore coat protein CotE. Little S, Driks A. Mol Microbiol 42 1107-1120 (2001)
  57. Immunoglobulin G1 Fc domain motions: implications for Fc engineering. Frank M, Walker RC, Lanzilotta WN, Prestegard JH, Barb AW. J Mol Biol 426 1799-1811 (2014)
  58. Optimization of RNA 3D structure prediction using evolutionary restraints of nucleotide-nucleotide interactions from direct coupling analysis. Wang J, Mao K, Zhao Y, Zeng C, Xiang J, Zhang Y, Xiao Y. Nucleic Acids Res 45 6299-6309 (2017)
  59. A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1. De Nardis C, Hendriks LJA, Poirier E, Arvinte T, Gros P, Bakker ABH, de Kruif J. J Biol Chem 292 14706-14717 (2017)
  60. In different organisms, the mode of interaction between two signaling proteins is not necessarily conserved. Park SY, Beel BD, Simon MI, Bilwes AM, Crane BR. Proc Natl Acad Sci U S A 101 11646-11651 (2004)
  61. Layer-by-layer assembly of multilayer films composed of avidin and biotin-labeled antibody for immunosensing. Cui X, Pei R, Wang Z, Yang F, Ma Y, Dong S, Yang X. Biosens Bioelectron 18 59-67 (2003)
  62. Anti-idiotypic protein domains selected from protein A-based affibody libraries. Eklund M, Axelsson L, Uhlén M, Nygren PA. Proteins 48 454-462 (2002)
  63. High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity. Bostrom J, Haber L, Koenig P, Kelley RF, Fuh G. PLoS One 6 e17887 (2011)
  64. Mutations in the MutSalpha interaction interface of MLH1 can abolish DNA mismatch repair. Plotz G, Welsch C, Giron-Monzon L, Friedhoff P, Albrecht M, Piiper A, Biondi RM, Lengauer T, Zeuzem S, Raedle J. Nucleic Acids Res 34 6574-6586 (2006)
  65. Protein A chromatography increases monoclonal antibody aggregation rate during subsequent low pH virus inactivation hold. Mazzer AR, Perraud X, Halley J, O'Hara J, Bracewell DG. J Chromatogr A 1415 83-90 (2015)
  66. TCR Signaling Emerges from the Sum of Many Parts. Kuhns MS, Davis MM. Front Immunol 3 159 (2012)
  67. MOrPH-PhD: An Integrated Phage Display Platform for the Discovery of Functional Genetically Encoded Peptide Macrocycles. Owens AE, Iannuzzelli JA, Gu Y, Fasan R. ACS Cent Sci 6 368-381 (2020)
  68. SiteLight: binding-site prediction using phage display libraries. Halperin I, Wolfson H, Nussinov R. Protein Sci 12 1344-1359 (2003)
  69. Catalytic and binding poly-reactivities shared by two unrelated proteins: The potential role of promiscuity in enzyme evolution. James LC, Tawfik DS. Protein Sci 10 2600-2607 (2001)
  70. Controlled antibody immobilization onto immunoanalytical platforms by synthetic peptide. Jung Y, Kang HJ, Lee JM, Jung SO, Yun WS, Chung SJ, Chung BH. Anal Biochem 374 99-105 (2008)
  71. Discovery of a novel small molecule binding site of human survivin. Wendt MD, Sun C, Kunzer A, Sauer D, Sarris K, Hoff E, Yu L, Nettesheim DG, Chen J, Jin S, Comess KM, Fan Y, Anderson SN, Isaac B, Olejniczak ET, Hajduk PJ, Rosenberg SH, Elmore SW. Bioorg Med Chem Lett 17 3122-3129 (2007)
  72. The structure of chagasin in complex with a cysteine protease clarifies the binding mode and evolution of an inhibitor family. Wang SX, Pandey KC, Scharfstein J, Whisstock J, Huang RK, Jacobelli J, Fletterick RJ, Rosenthal PJ, Abrahamson M, Brinen LS, Rossi A, Sali A, McKerrow JH. Structure 15 535-543 (2007)
  73. Silicon photonic micro-disk resonators for label-free biosensing. Grist SM, Schmidt SA, Flueckiger J, Donzella V, Shi W, Talebi Fard S, Kirk JT, Ratner DM, Cheung KC, Chrostowski L. Opt Express 21 7994-8006 (2013)
  74. Interaction of Ferredoxin-NADP(+) Reductase with its Substrates: Optimal Interaction for Efficient Electron Transfer. Medina M, Gómez-Moreno C. Photosynth Res 79 113-131 (2004)
  75. Pharmacological manipulation of transcription factor protein-protein interactions: opportunities and obstacles. Fontaine F, Overman J, François M. Cell Regen 4 2 (2015)
  76. Bordetella pertussis binds to human C4b-binding protein (C4BP) at a site similar to that used by the natural ligand C4b. Berggård K, Lindahl G, Dahlbäck B, Blom AM. Eur J Immunol 31 2771-2780 (2001)
  77. Using ligand-mapping simulations to design a ligand selectively targeting a cryptic surface pocket of polo-like kinase 1. Tan YS, Śledź P, Lang S, Stubbs CJ, Spring DR, Abell C, Best RB. Angew Chem Int Ed Engl 51 10078-10081 (2012)
  78. Bcl-XL-templated assembly of its own protein-protein interaction modulator from fragments decorated with thio acids and sulfonyl azides. Hu X, Sun J, Wang HG, Manetsch R. J Am Chem Soc 130 13820-13821 (2008)
  79. From crystal packing to molecular recognition: prediction and discovery of a binding site on the surface of polo-like kinase 1. Śledź P, Stubbs CJ, Lang S, Yang YQ, McKenzie GJ, Venkitaraman AR, Hyvönen M, Abell C. Angew Chem Int Ed Engl 50 4003-4006 (2011)
  80. Spatial chemical conservation of hot spot interactions in protein-protein complexes. Shulman-Peleg A, Shatsky M, Nussinov R, Wolfson HJ. BMC Biol 5 43 (2007)
  81. Structure of the BgK-Kv1.1 complex based on distance restraints identified by double mutant cycles. Molecular basis for convergent evolution of Kv1 channel blockers. Gilquin B, Racapé J, Wrisch A, Visan V, Lecoq A, Grissmer S, Ménez A, Gasparini S. J Biol Chem 277 37406-37413 (2002)
  82. The analysis of the human high affinity IgE receptor Fc epsilon Ri alpha from multiple crystal forms. Garman SC, Sechi S, Kinet JP, Jardetzky TS. J Mol Biol 311 1049-1062 (2001)
  83. The human cytomegalovirus Fc receptor gp68 binds the Fc CH2-CH3 interface of immunoglobulin G. Sprague ER, Reinhard H, Cheung EJ, Farley AH, Trujillo RD, Hengel H, Bjorkman PJ. J Virol 82 3490-3499 (2008)
  84. Affinity proteomics to study endogenous protein complexes: pointers, pitfalls, preferences and perspectives. LaCava J, Molloy KR, Taylor MS, Domanski M, Chait BT, Rout MP. Biotechniques 58 103-119 (2015)
  85. Experimental and computational analyses of the energetic basis for dual recognition of immunity proteins by colicin endonucleases. Keeble AH, Joachimiak LA, Maté MJ, Meenan N, Kirkpatrick N, Baker D, Kleanthous C. J Mol Biol 379 745-759 (2008)
  86. Developing an antibody-binding protein cage as a molecular recognition drug modular nanoplatform. Kang HJ, Kang YJ, Lee YM, Shin HH, Chung SJ, Kang S. Biomaterials 33 5423-5430 (2012)
  87. Development of small molecules designed to modulate protein-protein interactions. Che Y, Brooks BR, Marshall GR. J Comput Aided Mol Des 20 109-130 (2006)
  88. pH dependence and stoichiometry of binding to the Fc region of IgG by the herpes simplex virus Fc receptor gE-gI. Sprague ER, Martin WL, Bjorkman PJ. J Biol Chem 279 14184-14193 (2004)
  89. 'Double water exclusion': a hypothesis refining the O-ring theory for the hot spots at protein interfaces. Li J, Liu Q. Bioinformatics 25 743-750 (2009)
  90. Localization of protein-binding sites within families of proteins. Korkin D, Davis FP, Sali A. Protein Sci 14 2350-2360 (2005)
  91. Activation of the proapoptotic death receptor DR5 by oligomeric peptide and antibody agonists. Li B, Russell SJ, Compaan DM, Totpal K, Marsters SA, Ashkenazi A, Cochran AG, Hymowitz SG, Sidhu SS. J Mol Biol 361 522-536 (2006)
  92. Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics. Ying T, Chen W, Feng Y, Wang Y, Gong R, Dimitrov DS. J Biol Chem 288 25154-25164 (2013)
  93. Modular assembly of macrocyclic organo-peptide hybrids using synthetic and genetically encoded precursors. Smith JM, Vitali F, Archer SA, Fasan R. Angew Chem Int Ed Engl 50 5075-5080 (2011)
  94. Structure of the Epstein-Barr virus oncogene BARF1. Tarbouriech N, Ruggiero F, de Turenne-Tessier M, Ooka T, Burmeister WP. J Mol Biol 359 667-678 (2006)
  95. Energetic determinants of protein binding specificity: insights into protein interaction networks. Carbonell P, Nussinov R, del Sol A. Proteomics 9 1744-1753 (2009)
  96. Structural requirements for the interaction of human IgM and IgA with the human Fcalpha/mu receptor. Ghumra A, Shi J, Mcintosh RS, Rasmussen IB, Braathen R, Johansen FE, Sandlie I, Mongini PK, Areschoug T, Lindahl G, Lewis MJ, Woof JM, Pleass RJ. Eur J Immunol 39 1147-1156 (2009)
  97. A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2. Majdoubi A, Michalski C, O'Connell SE, Dada S, Narpala S, Gelinas J, Mehta D, Cheung C, Winkler DF, Basappa M, Liu AC, Görges M, Barakauskas VE, Irvine M, Mehalko J, Esposito D, Sekirov I, Jassem AN, Goldfarb DM, Pelech S, Douek DC, McDermott AB, Lavoie PM. JCI Insight 6 146316 (2021)
  98. Crystal structure of deglycosylated human IgG4-Fc. Davies AM, Jefferis R, Sutton BJ. Mol Immunol 62 46-53 (2014)
  99. Crystal structure of the catalytic domain of human bile salt activated lipase. Terzyan S, Wang CS, Downs D, Hunter B, Zhang XC. Protein Sci 9 1783-1790 (2000)
  100. Cyclic modular beta-sheets. Woods RJ, Brower JO, Castellanos E, Hashemzadeh M, Khakshoor O, Russu WA, Nowick JS. J Am Chem Soc 129 2548-2558 (2007)
  101. Noncovalent modification of chymotrypsin surface using an amphiphilic polymer scaffold: implications in modulating protein function. Sandanaraj BS, Vutukuri DR, Simard JM, Klaikherd A, Hong R, Rotello VM, Thayumanavan S. J Am Chem Soc 127 10693-10698 (2005)
  102. Optimization of the antibody C(H)3 domain by residue frequency analysis of IgG sequences. Demarest SJ, Rogers J, Hansen G. J Mol Biol 335 41-48 (2004)
  103. Engineered synthetic polymer nanoparticles as IgG affinity ligands. Lee SH, Hoshino Y, Randall A, Zeng Z, Baldi P, Doong RA, Shea KJ. J Am Chem Soc 134 15765-15772 (2012)
  104. Statistical analysis of physical-chemical properties and prediction of protein-protein interfaces. Negi SS, Braun W. J Mol Model 13 1157-1167 (2007)
  105. Letter Benzene Probes in Molecular Dynamics Simulations Reveal Novel Binding Sites for Ligand Design. Tan YS, Reeks J, Brown CJ, Thean D, Ferrer Gago FJ, Yuen TY, Goh ET, Lee XE, Jennings CE, Joseph TL, Lakshminarayanan R, Lane DP, Noble ME, Verma CS. J Phys Chem Lett 7 3452-3457 (2016)
  106. Ribosomal Synthesis of Macrocyclic Peptides in Vitro and in Vivo Mediated by Genetically Encoded Aminothiol Unnatural Amino Acids. Frost JR, Jacob NT, Papa LJ, Owens AE, Fasan R. ACS Chem Biol 10 1805-1816 (2015)
  107. Single-round, multiplexed antibody mimetic design through mRNA display. Olson CA, Nie J, Diep J, Al-Shyoukh I, Takahashi TT, Al-Mawsawi LQ, Bolin JM, Elwell AL, Swanson S, Stewart R, Thomson JA, Soh HT, Roberts RW, Sun R. Angew Chem Int Ed Engl 51 12449-12453 (2012)
  108. Structural basis for molecular recognition in an affibody:affibody complex. Lendel C, Dogan J, Härd T. J Mol Biol 359 1293-1304 (2006)
  109. Synthesis of bioactive and stabilized cyclic peptides by macrocyclization using C(sp3)-H activation. Tang J, He Y, Chen H, Sheng W, Wang H. Chem Sci 8 4565-4570 (2017)
  110. Lipoic acid stimulates cAMP production via the EP2 and EP4 prostanoid receptors and inhibits IFN gamma synthesis and cellular cytotoxicity in NK cells. Salinthone S, Schillace RV, Marracci GH, Bourdette DN, Carr DW. J Neuroimmunol 199 46-55 (2008)
  111. Modeling the binding sites of anti-hen egg white lysozyme antibodies HyHEL-8 and HyHEL-26: an insight into the molecular basis of antibody cross-reactivity and specificity. Mohan S, Sinha N, Smith-Gill SJ. Biophys J 85 3221-3236 (2003)
  112. Screening of protein-protein interaction modulators via sulfo-click kinetic target-guided synthesis. Kulkarni SS, Hu X, Doi K, Wang HG, Manetsch R. ACS Chem Biol 6 724-732 (2011)
  113. Structural basis for enhanced HIV-1 neutralization by a dimeric immunoglobulin G form of the glycan-recognizing antibody 2G12. Wu Y, West AP, Kim HJ, Thornton ME, Ward AB, Bjorkman PJ. Cell Rep 5 1443-1455 (2013)
  114. Binding site on human immunoglobulin G for the affinity ligand HWRGWV. Yang H, Gurgel PV, Williams DK, Bobay BG, Cavanagh J, Muddiman DC, Carbonell RG. J Mol Recognit 23 271-282 (2010)
  115. Dual targeting antibacterial peptide inhibitor of early lipid A biosynthesis. Jenkins RJ, Dotson GD. ACS Chem Biol 7 1170-1177 (2012)
  116. Template-constrained macrocyclic peptides prepared from native, unprotected precursors. Lawson KV, Rose TE, Harran PG. Proc Natl Acad Sci U S A 110 E3753-60 (2013)
  117. Characterization of therapeutic monoclonal antibodies reveals differences between in vitro and in vivo time-course studies. Yin S, Pastuskovas CV, Khawli LA, Stults JT. Pharm Res 30 167-178 (2013)
  118. Deregulations in the cyclin-dependent kinase-9-related pathway in cancer: implications for drug discovery and development. Romano G. ISRN Oncol 2013 305371 (2013)
  119. Free energies of protein-protein association determined by electrospray ionization mass spectrometry correlate accurately with values obtained by solution methods. Krishnaswamy SR, Williams ER, Kirsch JF. Protein Sci 15 1465-1475 (2006)
  120. Structure-templated predictions of novel protein interactions from sequence information. Betel D, Breitkreuz KE, Isserlin R, Dewar-Darch D, Tyers M, Hogue CW. PLoS Comput Biol 3 1783-1789 (2007)
  121. Xenoprotein engineering via synthetic libraries. Gates ZP, Vinogradov AA, Quartararo AJ, Bandyopadhyay A, Choo ZN, Evans ED, Halloran KH, Mijalis AJ, Mong SK, Simon MD, Standley EA, Styduhar ED, Tasker SZ, Touti F, Weber JM, Wilson JL, Jamison TF, Pentelute BL. Proc Natl Acad Sci U S A 115 E5298-E5306 (2018)
  122. 3dRNA: Building RNA 3D structure with improved template library. Zhang Y, Wang J, Xiao Y. Comput Struct Biotechnol J 18 2416-2423 (2020)
  123. A common theme in interaction of bacterial immunoglobulin-binding proteins with immunoglobulins illustrated in the equine system. Lewis MJ, Meehan M, Owen P, Woof JM. J Biol Chem 283 17615-17623 (2008)
  124. A new ligand for immunoglobulin g subdomains by screening of a synthetic peptide library. Verdoliva A, Marasco D, De Capua A, Saporito A, Bellofiore P, Manfredi V, Fattorusso R, Pedone C, Ruvo M. Chembiochem 6 1242-1253 (2005)
  125. Molecular modeling of protein A affinity chromatography. Salvalaglio M, Zamolo L, Busini V, Moscatelli D, Cavallotti C. J Chromatogr A 1216 8678-8686 (2009)
  126. A Robust Workflow for Native Mass Spectrometric Analysis of Affinity-Isolated Endogenous Protein Assemblies. Olinares PD, Dunn AD, Padovan JC, Fernandez-Martinez J, Rout MP, Chait BT. Anal Chem 88 2799-2807 (2016)
  127. Chicken IgY binds its receptor at the CH3/CH4 interface similarly as the human IgA: Fc alpha RI interaction. Pürzel J, Schmitt R, Viertlboeck BC, Göbel TW. J Immunol 183 4554-4559 (2009)
  128. Peptide ligands that use a novel binding site to target both TGF-β receptors. Li L, Orner BP, Huang T, Hinck AP, Kiessling LL. Mol Biosyst 6 2392-2402 (2010)
  129. A silicon photonic biosensor using phase-shifted Bragg gratings in slot waveguide. Wang X, Flueckiger J, Schmidt S, Grist S, Fard ST, Kirk J, Doerfler M, Cheung KC, Ratner DM, Chrostowski L. J Biophotonics 6 821-828 (2013)
  130. New insights into intra- and intermolecular interactions of immunoglobulins: crystal structure of mouse IgG2b-Fc at 2.1-A resolution. Kolenko P, Dohnálek J, Dusková J, Skálová T, Collard R, Hasek J. Immunology 126 378-385 (2009)
  131. Protein hot spots: the islands of stability. Kuttner YY, Engel S. J Mol Biol 415 419-428 (2012)
  132. Synthesis and biological evaluation of new pleuromutilin derivatives as antibacterial agents. Shang RF, Wang GH, Xu XM, Liu SJ, Zhang C, Yi YP, Liang JP, Liu Y. Molecules 19 19050-19065 (2014)
  133. Optimized sensitivity of Silicon-on-Insulator (SOI) strip waveguide resonator sensor. TalebiFard S, Schmidt S, Shi W, Wu W, Jaeger NA, Kwok E, Ratner DM, Chrostowski L. Biomed Opt Express 8 500-511 (2017)
  134. Antigen-Induced Allosteric Changes in a Human IgG1 Fc Increase Low-Affinity Fcγ Receptor Binding. Orlandi C, Deredge D, Ray K, Gohain N, Tolbert W, DeVico AL, Wintrode P, Pazgier M, Lewis GK. Structure 28 516-527.e5 (2020)
  135. Conformation-specific affinity purification of proteins using engineered binding proteins: application to the estrogen receptor. Huang J, Koide A, Nettle KW, Greene GL, Koide S. Protein Expr Purif 47 348-354 (2006)
  136. Convergent recognition of the IgE binding site on the high-affinity IgE receptor. Stamos J, Eigenbrot C, Nakamura GR, Reynolds ME, Yin J, Lowman HB, Fairbrother WJ, Starovasnik MA. Structure 12 1289-1301 (2004)
  137. Discovery and characterization of a peptide motif that specifically recognizes a non-native conformation of human IgG induced by acidic pH conditions. Sakamoto K, Ito Y, Hatanaka T, Soni PB, Mori T, Sugimura K. J Biol Chem 284 9986-9993 (2009)
  138. Diverse organo-peptide macrocycles via a fast and catalyst-free oxime/intein-mediated dual ligation. Satyanarayana M, Vitali F, Frost JR, Fasan R. Chem Commun (Camb) 48 1461-1463 (2012)
  139. Monte Carlo simulations of the peptide recognition at the consensus binding site of the constant fragment of human immunoglobulin G: the energy landscape analysis of a hot spot at the intermolecular interface. Verkhivker GM, Bouzida D, Gehlhaar DK, Rejto PA, Freer ST, Rose PW. Proteins 48 539-557 (2002)
  140. Protein design through systematic catalytic loop exchange in the (beta/alpha)8 fold. Ochoa-Leyva A, Soberón X, Sánchez F, Argüello M, Montero-Morán G, Saab-Rincón G. J Mol Biol 387 949-964 (2009)
  141. Reciprocal TCR-CD3 and CD4 Engagement of a Nucleating pMHCII Stabilizes a Functional Receptor Macrocomplex. Glassman CR, Parrish HL, Lee MS, Kuhns MS. Cell Rep 22 1263-1275 (2018)
  142. Cloning and characterization of the dromedary (Camelus dromedarius) neonatal Fc receptor (drFcRn). Kacskovics I, Mayer B, Kis Z, Frenyó LV, Zhao Y, Muyldermans S, Hammarström L. Dev Comp Immunol 30 1203-1215 (2006)
  143. Dynamic and equilibrium performance of sensors based on short peptide ligands for affinity adsorption of human IgG using surface plasmon resonance. Islam N, Shen F, Gurgel PV, Rojas OJ, Carbonell RG. Biosens Bioelectron 58 380-387 (2014)
  144. Empirical estimation of the energetic contribution of individual interface residues in structures of protein-protein complexes. Guharoy M, Chakrabarti P. J Comput Aided Mol Des 23 645-654 (2009)
  145. FcαRI binding at the IgA1 CH2-CH3 interface induces long-range conformational changes that are transmitted to the hinge region. Posgai MT, Tonddast-Navaei S, Jayasinghe M, Ibrahim GM, Stan G, Herr AB. Proc Natl Acad Sci U S A 115 E8882-E8891 (2018)
  146. Low-stringency selection of TEM1 for BLIP shows interface plasticity and selection for faster binders. Cohen-Khait R, Schreiber G. Proc Natl Acad Sci U S A 113 14982-14987 (2016)
  147. NMR analysis of G-protein betagamma subunit complexes reveals a dynamic G(alpha)-Gbetagamma subunit interface and multiple protein recognition modes. Smrcka AV, Kichik N, Tarragó T, Burroughs M, Park MS, Itoga NK, Stern HA, Willardson BM, Giralt E. Proc Natl Acad Sci U S A 107 639-644 (2010)
  148. Antibody blood-brain barrier efflux is modulated by glycan modification. Finke JM, Ayres KR, Brisbin RP, Hill HA, Wing EE, Banks WA. Biochim Biophys Acta Gen Subj 1861 2228-2239 (2017)
  149. Evolutionary transition pathways for changing peptide ligand specificity and structure. Hoffmüller U, Knaute T, Hahn M, Höhne W, Schneider-Mergener J, Kramer A. EMBO J 19 4866-4874 (2000)
  150. Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells. Tammen A, Derer S, Schwanbeck R, Rösner T, Kretschmer A, Beurskens FJ, Schuurman J, Parren PW, Valerius T. J Immunol 198 1585-1594 (2017)
  151. TriFabs--Trivalent IgG-Shaped Bispecific Antibody Derivatives: Design, Generation, Characterization and Application for Targeted Payload Delivery. Mayer K, Baumann AL, Grote M, Seeber S, Kettenberger H, Breuer S, Killian T, Schäfer W, Brinkmann U. Int J Mol Sci 16 27497-27507 (2015)
  152. Beauty is in the eye of the beholder: proteins can recognize binding sites of homologous proteins in more than one way. Martin J. PLoS Comput Biol 6 e1000821 (2010)
  153. Six amino acid residues in a 1200 Å2 interface mediate binding of factor VIII to an IgG4κ inhibitory antibody. Lin JC, Ettinger RA, Schuman JT, Zhang AH, Wamiq-Adhami M, Nguyen PC, Nakaya-Fletcher SM, Puranik K, Thompson AR, Pratt KP. PLoS One 10 e0116577 (2015)
  154. A general process for the development of peptide-based immunoassays for monoclonal antibodies. Sanchez AB, Nguyen T, Dema-Ala R, Kummel AC, Kipps TJ, Messmer BT. Cancer Chemother Pharmacol 66 919-925 (2010)
  155. Computational analysis of ligand binding dynamics at the intermolecular hot spots with the aid of simulated tempering and binding free energy calculations. Verkhivker GM. J Mol Graph Model 22 335-348 (2004)
  156. How do two unrelated antibodies, HyHEL-10 and F9.13.7, recognize the same epitope of hen egg-white lysozyme? Pons J, Stratton JR, Kirsch JF. Protein Sci 11 2308-2315 (2002)
  157. Implication of C-terminal deletion on the structure and stability of bovine beta-casein. Qi PX, Wickham ED, Piotrowski EG, Fagerquist CK, Farrell HM. Protein J 24 431-444 (2005)
  158. Introduction of the YTE mutation into the non-immunogenic HIV bnAb PGT121 induces anti-drug antibodies in macaques. Rosenberg YJ, Lewis GK, Montefiori DC, LaBranche CC, Lewis MG, Urban LA, Lees JP, Mao L, Jiang X. PLoS One 14 e0212649 (2019)
  159. Screening Outside the Catalytic Site: Inhibition of Macromolecular Inter-actions Through Structure-Based Virtual Ligand Screening Experiments. Sperandio O, Miteva MA, Segers K, Nicolaes GA, Villoutreix BO. Open Biochem J 2 29-37 (2008)
  160. A modular synthesis of teraryl-based α-helix mimetics, part 1: Synthesis of core fragments with two electronically differentiated leaving groups. Peters M, Trobe M, Tan H, Kleineweischede R, Breinbauer R. Chemistry 19 2442-2449 (2013)
  161. Comparison of sea anemone and scorpion toxins binding to Kv1 channels: an example of convergent evolution. Gasparini S, Gilquin B, Ménez A. Toxicon 43 901-908 (2004)
  162. Enzymatically biocatalytic precipitates amplified antibody-antigen interaction for super low level immunoassay: an investigation combined surface plasmon resonance with electrochemistry. Tang H, Wang Q, Xie Q, Zhang Y, Tan L, Yao S. Biosens Bioelectron 23 668-674 (2007)
  163. Identification of protein-protein interfaces implicated in CD80-CD28 costimulatory signaling. Sørensen P, Kussmann M, Rosén A, Bennett KL, Thrige Dda G, Uvebrant K, Walse B, Roepstorff P, Björk P. J Immunol 172 6803-6809 (2004)
  164. Prediction of protein binding regions. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Proteins 79 888-897 (2011)
  165. Solvent-accessible surface area: How well can be applied to hot-spot detection? Martins JM, Ramos RM, Pimenta AC, Moreira IS. Proteins 82 479-490 (2014)
  166. Structural basis for biomolecular recognition in overlapping binding sites in a diiron enzyme system. Acheson JF, Bailey LJ, Elsen NL, Fox BG. Nat Commun 5 5009 (2014)
  167. The ACE2-binding Interface of SARS-CoV-2 Spike Inherently Deflects Immune Recognition. Hattori T, Koide A, Noval MG, Panchenko T, Romero LA, Teng KW, Tada T, Landau NR, Stapleford KA, Koide S. J Mol Biol 433 166748 (2021)
  168. The structural plasticity of the C terminus of p21Cip1 is a determinant for target protein recognition. Esteve V, Canela N, Rodriguez-Vilarrupla A, Aligué R, Agell N, Mingarro I, Bachs O, Pérez-Payá E. Chembiochem 4 863-869 (2003)
  169. Amino acid determinants of beta-hairpin conformation in erythropoeitin receptor agonist peptides derived from a phage display library. Skelton NJ, Russell S, de Sauvage F, Cochran AG. J Mol Biol 316 1111-1125 (2002)
  170. Anti-HLA antibodies with complementary and synergistic interaction geometries promote classical complement activation on platelets. Rijkers M, Schmidt D, Lu N, Kramer CSM, Heidt S, Mulder A, Porcelijn L, Claas FHJ, Leebeek FWG, Jansen AJG, Jongerius I, Zeerleder SS, Vidarsson G, Voorberg J, de Haas M. Haematologica 104 403-416 (2019)
  171. Chemical synthesis and biological activities of novel pleuromutilin derivatives with substituted amino moiety. Shang R, Wang S, Xu X, Yi Y, Guo W, Yuliu, Liang J. PLoS One 8 e82595 (2013)
  172. Exploring the binding nature of pyrrolidine pocket-dependent interactions in the polo-box domain of polo-like kinase 1. Murugan RN, Ahn M, Lee WC, Kim HY, Song JH, Cheong C, Hwang E, Seo JH, Shin SY, Choi SH, Park JE, Bang JK. PLoS One 8 e80043 (2013)
  173. Fc-binding antibody-recruiting molecules exploit endogenous antibodies for anti-tumor immune responses. Sasaki K, Harada M, Miyashita Y, Tagawa H, Kishimura A, Mori T, Katayama Y. Chem Sci 11 3208-3214 (2020)
  174. Identification of cyclic peptides able to mimic the functional epitope of IgG1-Fc for human Fc gammaRI. Bonetto S, Spadola L, Buchanan AG, Jermutus L, Lund J. FASEB J 23 575-585 (2009)
  175. Role of β-lactamase residues in a common interface for binding the structurally unrelated inhibitory proteins BLIP and BLIP-II. Fryszczyn BG, Adamski CJ, Brown NG, Rice K, Huang W, Palzkill T. Protein Sci 23 1235-1246 (2014)
  176. Structure based antibody-like peptidomimetics. Murali R, Greene MI. Pharmaceuticals (Basel) 5 209-235 (2012)
  177. Characterization of immunoglobulin binding by schistosomes. McIntosh RS, Jones FM, Dunne DW, McKerrow JH, Pleass RJ. Parasite Immunol 28 407-419 (2006)
  178. Effects of interface mutations on the dimerization of alanine glyoxylate aminotransferase and implications in the mistargeting of the pathogenic variants F152I and I244T. Dindo M, Montioli R, Busato M, Giorgetti A, Cellini B, Borri Voltattorni C. Biochimie 131 137-148 (2016)
  179. Functional characterization of APOBEC-1 complementation factor phosphorylation sites. Lehmann DM, Galloway CA, MacElrevey C, Sowden MP, Wedekind JE, Smith HC. Biochim Biophys Acta 1773 408-418 (2007)
  180. Localization of the equine IgG-binding domain in the fibrinogen-binding protein (FgBP) of Streptococcus equi subsp. equi. Meehan M, Lewis MJ, Byrne C, O'Hare D, Woof JM, Owen P. Microbiology (Reading) 155 2583-2592 (2009)
  181. Selection and characterization of cyclic peptides that bind to a monoclonal antibody against meningococcal L3,7,9 lipopolysaccharides. Lauvrak V, Berntzen G, Heggelund U, Herstad TK, Sandin RH, Dalseg R, Rosenqvist E, Sandlie I, Michaelsen TE. Scand J Immunol 59 373-384 (2004)
  182. 3dDNA: A Computational Method of Building DNA 3D Structures. Zhang Y, Xiong Y, Xiao Y. Molecules 27 5936 (2022)
  183. A homogeneous assay for protein analysis in droplets by fluorescence polarization. Joensson HN, Zhang C, Uhlén M, Andersson-Svahn H. Electrophoresis 33 436-439 (2012)
  184. Depletion of albumin and immunoglobulin G from human serum using epitope-imprinted polymers as artificial antibodies. Yang HH, Lu KH, Lin YF, Tsai SH, Chakraborty S, Zhai WJ, Tai DF. J Biomed Mater Res A 101 1935-1942 (2013)
  185. Efficient selection of IgG Fc domain-binding peptides fused to fluorescent protein using E. coli expression system and dot-blotting assay. Jeong YJ, Kang HJ, Bae KH, Kim MG, Chung SJ. Peptides 31 202-206 (2010)
  186. Grafting of functional motifs onto protein scaffolds identified by PDB screening--an efficient route to design optimizable protein binders. Tlatli R, Nozach H, Collet G, Beau F, Vera L, Stura E, Dive V, Cuniasse P. FEBS J 280 139-159 (2013)
  187. Improved native isolation of endogenous Protein A-tagged protein complexes. LaCava J, Chandramouli N, Jiang H, Rout MP. Biotechniques 54 213-216 (2013)
  188. Quantitation and modeling of post-translational modifications in a therapeutic monoclonal antibody from single- and multiple-dose monkey pharmacokinetic studies using mass spectrometry. Xu X, Huang Y, Pan H, Molden R, Qiu H, Daly TJ, Li N. PLoS One 14 e0223899 (2019)
  189. Recognition of IgG-derived peptides by a human IgM with an unusual combining site. Yuriev E, Ramsland PA, Edmundson AB. Scand J Immunol 55 242-255 (2002)
  190. The structure of Fc receptor/Ig complexes: considerations on stoichiometry and potential inhibitors. Sondermann P, Oosthuizen V. Immunol Lett 82 51-56 (2002)
  191. A Fab-Selective Immunoglobulin-Binding Domain from Streptococcal Protein G with Improved Half-Life Extension Properties. Unverdorben F, Hutt M, Seifert O, Kontermann RE. PLoS One 10 e0139838 (2015)
  192. An ecoimmunological approach to study evolutionary and ancient links between coagulation, complement and Innate immunity. Papareddy P, Kasetty G, Alyafei S, Smeds E, Salo-Ahen OMH, Hansson SR, Egesten A, Herwald H. Virulence 9 724-737 (2018)
  193. Binding structures and energies of the human neonatal Fc receptor with human Fc and its mutants by molecular modeling and dynamics simulations. Huang X, Zheng F, Zhan CG. Mol Biosyst 9 3047-3058 (2013)
  194. CH2 domain orientation of human immunoglobulin G in solution: Structural comparison of glycosylated and aglycosylated Fc regions using small-angle X-ray scattering. Yageta S, Imamura H, Shibuya R, Honda S. MAbs 11 453-462 (2019)
  195. Deep learning of protein sequence design of protein-protein interactions. Syrlybaeva R, Strauch EM. Bioinformatics 39 btac733 (2023)
  196. Modulation of protein A binding allows single-step purification of mouse bispecific antibodies that retain FcRn binding. Zwolak A, Armstrong AA, Tam SH, Pardinas JR, Goulet DR, Zheng S, Brosnan K, Emmell E, Luo J, Gilliland GL, Chiu ML. MAbs 9 1306-1316 (2017)
  197. Molecular insights into the binding selectivity of a synthetic ligand DAAG to Fc fragment of IgG. Wang RZ, Lin DQ, Tong HF, Yao SJ. J Mol Recognit 27 250-259 (2014)
  198. Protein assembly directed by synthetic molecular recognition motifs. Ma M, Bong D. Org Biomol Chem 9 7296-7299 (2011)
  199. Structure networks of E. coli glutaminyl-tRNA synthetase: effects of ligand binding. Sathyapriya R, Vishveshwara S. Proteins 68 541-550 (2007)
  200. Viscosity Prediction of High-Concentration Antibody Solutions with Atomistic Simulations. Prass TM, Garidel P, Blech M, Schäfer LV. J Chem Inf Model 63 6129-6140 (2023)
  201. An encodable lanthanide binding tag with reduced size and flexibility for measuring residual dipolar couplings and pseudocontact shifts in large proteins. Barb AW, Subedi GP. J Biomol NMR 64 75-85 (2016)
  202. Engineered improvements in DNA-binding function of the MATa1 homeodomain reveal structural changes involved in combinatorial control. Hart B, Mathias JR, Ott D, McNaughton L, Anderson JS, Vershon AK, Baxter SM. J Mol Biol 316 247-256 (2002)
  203. Genetic elimination of α3(IV) collagen fails to rescue anti-collagen B cells. Clark AG, Mackin KM, Foster MH. Immunol Lett 141 134-139 (2011)
  204. Hot-spot analysis to dissect the functional protein-protein interface of a tRNA-modifying enzyme. Jakobi S, Nguyen TX, Debaene F, Metz A, Sanglier-Cianférani S, Reuter K, Klebe G. Proteins 82 2713-2732 (2014)
  205. Neutron reflectivity measurement of protein A-antibody complex at the solid-liquid interface. Mazzer AR, Clifton LA, Perevozchikova T, Butler PD, Roberts CJ, Bracewell DG. J Chromatogr A 1499 118-131 (2017)
  206. One site fits both: a model for the ternary complex of folate + NADPH in R67 dihydrofolate reductase, a D2 symmetric enzyme. Howell EE, Shukla U, Hicks SN, Smiley RD, Kuhn LA, Zavodszky MI. J Comput Aided Mol Des 15 1035-1052 (2001)
  207. Protein G, protein A and protein A-derived peptides inhibit the agitation induced aggregation of IgG. Zhang J, Topp EM. Mol Pharm 9 622-628 (2012)
  208. Surface dynamics in allosteric regulation of protein-protein interactions: modulation of calmodulin functions by Ca2+. Kuttner YY, Nagar T, Engel S. PLoS Comput Biol 9 e1003028 (2013)
  209. Understanding the impact of Fc glycosylation on its conformational changes by molecular dynamics simulations and bioinformatics. Zhang Y. Mol Biosyst 11 3415-3424 (2015)
  210. β-Hairpins as peptidomimetics of human phosphoprotein-binding domains. Batalha IL, Lychko I, Branco RJF, Iranzo O, Roque ACA. Org Biomol Chem 17 3996-4004 (2019)
  211. Cyclic peptide ligand with high binding capacity for affinity purification of immunoglobulin G. Kang HJ, Choe W, Min JK, Lee YM, Kim BM, Chung SJ. J Chromatogr A 1466 105-112 (2016)
  212. Rapid preparation of stable isotope labeled peptides that bind to target proteins by a phage library system. Mizukoshi Y, Takahashi H, Shimada I. J Biomol NMR 34 23-30 (2006)
  213. A peptide inhibitor of antibody-dependent cell-mediated cytotoxicity against EGFR/folate receptor-α double positive cells. Sasaki K, Miyashita Y, Asai D, Funamoto D, Sato K, Yamaguchi Y, Mishima Y, Iino T, Takaishi S, Nagano J, Kishimura A, Mori T, Katayama Y. Medchemcomm 9 783-788 (2018)
  214. Characterization of deamidation at Asn138 in L-chain of recombinant humanized Fab expressed from Pichia pastoris. Ohkuri T, Murase E, Sun SL, Sugitani J, Ueda T. J Biochem 154 333-340 (2013)
  215. Demonstration of intracellular trafficking, cytosolic bioavailability, and target manipulation of an antibody delivery platform. Lv W, Champion JA. Nanomedicine 32 102315 (2021)
  216. Discovery of antagonist peptides against bacterial helicase-primase interaction in B. stearothermophilus by reverse yeast three-hybrid. Gardiner L, Coyle BJ, Chan WC, Soultanas P. Chem Biol 12 595-604 (2005)
  217. Integration of cell-free protein coexpression with an enzyme-linked immunosorbent assay enables rapid analysis of protein-protein interactions directly from DNA. Layton CJ, Hellinga HW. Protein Sci 20 1432-1438 (2011)
  218. Promoting Fc-Fc interactions between anti-capsular antibodies provides strong immune protection against Streptococcus pneumoniae. Aguinagalde Salazar L, den Boer MA, Castenmiller SM, Zwarthoff SA, de Haas C, Aerts PC, Beurskens FJ, Schuurman J, Heck AJR, van Kessel K, Rooijakkers SHM. Elife 12 e80669 (2023)
  219. Solution immersed silicon (SIS)-based biosensors: a new approach in biosensing. Diware MS, Cho HM, Chegal W, Cho YJ, Jo JH, O SW, Paek SH, Yoon YH, Kim D. Analyst 140 706-709 (2015)
  220. Comment The single cell as a microplate well. Wittrup KD. Nat Biotechnol 18 1039-1040 (2000)
  221. Warren L. DeLano 21 June 1972-3 November 2009. Brunger AT, Wells JA. Nat Struct Mol Biol 16 1202-1203 (2009)
  222. A general platform for antibody purification utilizing engineered-micelles. Dhandapani G, Howard A, Truong TV, Baiju TV, Kesselman E, Friedman N, Wachtel E, Sheves M, Danino D, Namboothiri INN, Patchornik G. MAbs 11 583-592 (2019)
  223. Affinity polymers tailored for the protein A binding site of immunoglobulin G proteins. Latza P, Gilles P, Schaller T, Schrader T. Chemistry 20 11479-11487 (2014)
  224. Are hot-spots occluded from water? Moreira IS, Ramos RM, Martins JM, Fernandes PA, Ramos MJ. J Biomol Struct Dyn 32 186-197 (2014)
  225. Constant domain polymorphisms influence monoclonal antibody stability and dynamics. Warrender AK, Pan J, Pudney CR, Arcus VL, Kelton W. Protein Sci 32 e4589 (2023)
  226. Dual surface selection methodology for the identification of thrombin binding epitopes from hotspot biased phage-display libraries. Rajagopal S, Meza-Romero R, Ghosh I. Bioorg Med Chem Lett 14 1389-1393 (2004)
  227. Effects of the Fc-III tag on activity and stability of green fluorescent protein and human muscle creatine kinase. Feng S, Gong Y, Adilijiang G, Deng H. Protein Sci 22 1008-1015 (2013)
  228. Evolutional selection of a combinatorial phage library displaying randomly-rearranged various single domains of immunoglobulin (Ig)-binding proteins (IBPs) with four kinds of Ig molecules. Yang H, Cao J, Li LQ, Zhou X, Chen QL, Liao WT, Wen ZM, Jiang SH, Xu R, Jia JA, Pan X, Qi ZT, Pan W. BMC Microbiol 8 137 (2008)
  229. Exploration of O-GlcNAc transferase glycosylation sites reveals a target sequence compositional bias. Chong PA, Nosella ML, Vanama M, Ruiz-Arduengo R, Forman-Kay JD. J Biol Chem 299 104629 (2023)
  230. Hepatitis B surface antigen-antibody interactions studied by optical tweezers. Zhou ZL, Tang B, Tang B, Ngan AH, Dong ZN, Wu YS. IET Nanobiotechnol 6 9-15 (2012)
  231. Mapping and characterization of the interaction interface between two polypyrimidine-tract binding proteins and a nova-type protein of Solanum tuberosum. Shah S, Butler NM, Hannapel DJ, Rao AG. PLoS One 8 e64783 (2013)
  232. Molecular modeling to rationalize ligand-support interactions in affinity chromatography. Salvalaglio M, Cavallotti C. J Sep Sci 35 7-19 (2012)
  233. Molecular recognition of Fc-specific ligands binding onto the consensus binding site of IgG: insights from molecular simulation. Tong HF, Lin DQ, Zhang QL, Wang RZ, Yao SJ. J Mol Recognit 27 501-509 (2014)
  234. Multilevel regulation of protein-protein interactions in biological circuitry. Beckett D. Phys Biol 2 S67-73 (2005)
  235. Prefusion spike protein stabilization through computational mutagenesis. Zhang DY, Wang J, Dokholyan NV. Proteins 89 399-408 (2021)
  236. Surface mediated cooperative interactions of drugs enhance mechanical forces for antibiotic action. Ndieyira JW, Bailey J, Patil SB, Vögtli M, Cooper MA, Abell C, McKendry RA, Aeppli G. Sci Rep 7 41206 (2017)
  237. Systematic mutation and thermodynamic analysis of central tyrosine pairs in polyspecific NKG2D receptor interactions. Culpepper DJ, Maddox MK, Caldwell AB, McFarland BJ. Mol Immunol 48 516-523 (2011)
  238. Two Antibody-Guided Lactic-co-Glycolic Acid-Polyethylenimine (LGA-PEI) Nanoparticle Delivery Systems for Therapeutic Nucleic Acids. Lü JM, Liang Z, Liu D, Zhan B, Yao Q, Chen C. Pharmaceuticals (Basel) 14 841 (2021)
  239. 2,6,9-Trisubstituted purine derivatives as protein A mimetics for the treatment of autoimmune diseases. Zacharie B, Fortin D, Wilb N, Bienvenu JF, Asselin M, Grouix B, Penney C. Bioorg Med Chem Lett 19 242-246 (2009)
  240. A phage-displayed disulfide constrained peptide discovery platform yields novel human plasma protein binders. Gao X, Kaluarachchi H, Zhang Y, Hwang S, Hannoush RN. PLoS One 19 e0299804 (2024)
  241. Adaptive Assembly: Maximizing the Potential of a Given Functional Peptide with a Tailor-Made Protein Scaffold. Watanabe H, Honda S. Chem Biol 22 1165-1173 (2015)
  242. Artificial DnaJ Protein for protein production and conformational diseases. Hishiya A, Koya K. Sci Rep 7 8531 (2017)
  243. C1q-binding peptides share sequence similarity with C4 and induce complement activation. Messmer BT, Thaler DS. Mol Immunol 37 343-350 (2000)
  244. Evaluation of HSV-2 gE Binding to IgG-Fc and Application for Vaccine Development. Galli JD, Horton M, Durr E, Heidecker GJ, Freed D, Fridman A, Wang D, Zhang L. Vaccines (Basel) 10 184 (2022)
  245. Extending the applicability of the O-ring theory to protein-DNA complexes. Ramos RM, Fernandes LF, Moreira IS. Comput Biol Chem 44 31-39 (2013)
  246. On-column disulfide bond formation of monoclonal antibodies during Protein A chromatography eliminates low molecular weight species and rescues reduced antibodies. Tan Z, Ehamparanathan V, Ren T, Tang P, Hoffman L, Kuang J, Liu P, Huang C, Du C, Tao L, Chemmalil L, Lewandowski A, Ghose S, Li ZJ, Liu S. MAbs 12 1829333 (2020)
  247. Pharmacokinetic Engineering of OX40-Blocking Anticalin Proteins Using Monomeric Plasma Half-Life Extension Domains. Siegemund M, Oak P, Hansbauer EM, Allersdorfer A, Utschick K, Winter A, Grasmüller C, Galler G, Mayer JP, Weiche B, Prassler J, Kontermann RE, Rothe C. Front Pharmacol 12 759337 (2021)
  248. Phenotype and Neuronal Cytotoxic Function of Glioblastoma Extracellular Vesicles. Zhou W, Lovasz D, Zizzo Z, He Q, Coughlan C, Kowalski RG, Kennedy PGE, Graner AN, Lillehei KO, Ormond DR, Youssef AS, Graner MW, Yu X. Biomedicines 10 2718 (2022)
  249. The identification of affinity peptide ligands specific to the variable region of human antibodies. Akiyama Y, Miyata H, Komiyama M, Nogami M, Ozawa K, Oshita C, Kume A, Ashizawa T, Sakura N, Mochizuki T, Yamaguchi K. Biomed Res 35 105-116 (2014)
  250. Three ParA Dimers Cooperatively Assemble on Type Ia Partition Promoters. Boudsocq F, Salhi M, Barbe S, Bouet JY. Genes (Basel) 12 1345 (2021)
  251. Design of Tetra-Peptide Ligands of Antibody Fc Regions Using In Silico Combinatorial Library Screening. Jukič M, Kralj S, Kolarič A, Bren U. Pharmaceuticals (Basel) 16 1170 (2023)
  252. Development of the Fc-III tagged protein expression system for protein purification and detection. Feng S, Tian E, Zhang L, Wang Q, Deng H. PLoS One 7 e44208 (2012)
  253. Flexibility of BIV TAR-Tat: models of peptide binding. Hsieh M, Collins ED, Blomquist T, Lustig B. J Biomol Struct Dyn 20 243-251 (2002)
  254. Geometric frustration in the myosin superlattice of vertebrate muscle. Millane RP, Wojtas DH, Hong Yoon C, Blakeley ND, Bones PJ, Goyal A, Squire JM, Luther PK. J R Soc Interface 18 20210585 (2021)
  255. In vitro molecular evolution yields an NEIBM with a potential novel IgG binding property. Qi P, Ding YY, He T, Yang T, Chen Q, Feng J, Wang J, Cao M, Li X, Peng H, Zhu H, Cao J, Pan W. Sci Rep 4 6908 (2014)
  256. MOrPH-PhD: A Phage Display System for the Functional Selection of Genetically Encoded Macrocyclic Peptides. Gu Y, Iannuzzelli JA, Fasan R. Methods Mol Biol 2371 261-286 (2022)
  257. Mutation of UDP-glucose binding motif residues lead to increased affinity for ADP-glucose in sugarcane sucrose phosphate synthase. Kurniah NI, Sawitri WD, Rohman MS, Nugraha Y, Hase T, Sugiharto B. Mol Biol Rep 48 1697-1706 (2021)
  258. Phage-based molecular directed evolution yields multiple tandem human IgA affibodies with intramolecular binding avidity. Cao J, Wen ZM, Deng SH, Zhou X, Chen QL, Liao WT, Jiang SH, Jia JA, Qi ZT, Sun SH, Pan W. J Biotechnol 158 120-127 (2012)
  259. Purification of antibody fragments via interaction with detergent micellar aggregates. Dhandapani G, Wachtel E, Das I, Sheves M, Patchornik G. Sci Rep 11 11697 (2021)
  260. Quantitative Recoveries of Exosomes and Monoclonal Antibodies from Chinese Hamster Ovary Cell Cultures by Use of a Single, Integrated Two-Dimensional Liquid Chromatography Method. Wysor SK, Marcus RK. Anal Chem 95 17886-17893 (2023)
  261. The electrostatic role of the Zn-Cys2His2 complex in binding of operator DNA with transcription factors: mouse EGR-1 from the Cys2His2 family. Chirgadze YN, Boshkova EA, Polozov RV, Sivozhelezov VS, Dzyabchenko AV, Kuzminsky MB, Stepanenko VA, Ivanov VV. J Biomol Struct Dyn 36 3902-3915 (2018)
  262. The pearl necklace model in protein A chromatography: Molecular mechanisms at the resin interface. L Silva G, Plewka J, Lichtenegger H, Dias-Cabral AC, Jungbauer A, Tscheließnig R. Biotechnol Bioeng 116 76-86 (2019)
  263. Use of Solvent Mapping for Characterizing the Binding Site and for Predicting the Inhibition of the Human Ether-á-Go-Go-Related K+ Channel. Ma S, Sun Z, Jing Y, McGann M, Vajda S, Enyedy IJ. Chem Res Toxicol 35 1359-1369 (2022)
  264. A Machine Learning Approach to Identify Key Residues Involved in Protein-Protein Interactions Exemplified with SARS-CoV-2 Variants. Quitté L, Leclercq M, Prunier J, Scott-Boyer MP, Moroy G, Droit A. Int J Mol Sci 25 6535 (2024)
  265. An anchoring molecule increases intravitreal retention of antibody-based therapeutics used in the treatment of ocular diseases. Gao Q, Schachar IH. J Control Release 328 263-275 (2020)
  266. Design of inhibitor peptide sequences based on the interfacial knowledge of the protein G-IgG crystallographic complex and their binding studies with IgG. Tanwar N, Ojha R, Aggarwal S, Prajapati VK, Munde M. Eur Biophys J 53 159-170 (2024)
  267. Functionalisation of Inorganic Material Surfaces with Staphylococcus Protein A: A Molecular Dynamics Study. Farouq MAH, Kubiak-Ossowska K, Al Qaraghuli MM, Ferro VA, Mulheran PA. Int J Mol Sci 23 4832 (2022)
  268. Identification and Characterization of Novel Fc-Binding Heptapeptides from Experiments and Simulations. Sun X, Weaver J, Wickramasinghe SR, Qian X. Polymers (Basel) 10 E778 (2018)
  269. In Silico Exploration of the Trypanothione Reductase (TryR) of L. mexicana. Barrera-Téllez FJ, Prieto-Martínez FD, Hernández-Campos A, Martínez-Mayorga K, Castillo-Bocanegra R. Int J Mol Sci 24 16046 (2023)
  270. Major Factors for the Persistent Folding of Hybrid α, β, γ-Hybrid Peptides Into Hairpins. Zhong Y, Tang Q, Miller DP, Zurek E, Liu R, Lu ZL, Gong B. Front Chem 8 530083 (2020)
  271. Noncovalently particle-anchored cytokines with prolonged tumor retention safely elicit potent antitumor immunity. Niu L, Jang E, Chin AL, Huo Z, Wang W, Cai W, Tong R. Sci Adv 10 eadk7695 (2024)


Quick links